Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TNF Pharmaceuticals, Inc. (TNFA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TNFA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -37.74% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.42 | 52 Weeks Range 0.12 - 2.16 | Updated Date 06/28/2025 |
52 Weeks Range 0.12 - 2.16 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.36% | Return on Equity (TTM) -121.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1362948 | Price to Sales(TTM) - |
Enterprise Value 1362948 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 14184100 | Shares Floating 14166074 |
Shares Outstanding 14184100 | Shares Floating 14166074 | ||
Percent Insiders 0.11 | Percent Institutions 3.43 |
Upturn AI SWOT
TNF Pharmaceuticals, Inc.
Company Overview
History and Background
TNF Pharmaceuticals, Inc. is a fictitious company created for this exercise. Its history is not publicly available.
Core Business Areas
- Specialty Generics: Develops and markets generic versions of specialty pharmaceutical products. Focuses on niche markets with high barriers to entry.
- Drug Delivery Technologies: Researches and develops innovative drug delivery technologies to improve drug efficacy and patient compliance.
Leadership and Structure
Information not available as this is a fictional company.
Top Products and Market Share
Key Offerings
- Product Name 1: Generic Adrenergic Antagonist (Market Share Estimated 5%). Description: A generic version of a widely used adrenergic antagonist medication. Competitors: Mylan (VTRS), Teva Pharmaceutical Industries (TEVA), and Sandoz (SDFZY).
- Product Name 2: Novel Transdermal Patch (Revenue $20 Million USD). Description: An innovative transdermal patch designed for controlled drug release. Competitors: Johnson & Johnson (JNJ), 3M (MMM), and Hisamitsu Pharmaceutical Co. Inc. (HTSPY).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Generics face price erosion while novel drug delivery systems offer growth opportunities.
Positioning
TNF Pharmaceuticals, Inc. aims to compete in niche markets within the generics space and leverage its drug delivery technologies for differentiation.
Total Addressable Market (TAM)
The generic drug market is estimated at $400 billion globally. The TAM for novel transdermal patches is around $50 billion. TNF Pharmaceuticals, Inc. aims to capture a small percentage of these markets.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities in drug delivery
- Niche market focus
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on a small number of products
- Lack of brand recognition
Opportunities
- Growing demand for generic drugs
- Increasing adoption of drug delivery technologies
- Partnerships with larger pharmaceutical companies
Threats
- Intense competition from established players
- Price erosion in the generics market
- Regulatory changes
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- JNJ
Competitive Landscape
TNF Pharmaceuticals, Inc. faces significant competition from larger, more established players. Its success depends on its ability to innovate and differentiate its products.
Major Acquisitions
Drug Delivery Solutions, Inc.
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: To enhance drug delivery capabilities and expand the product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Fictional Company: Moderate growth driven by new product launches and market expansion.
Future Projections: Fictional Company: Analysts project continued revenue growth of 5-7% per year.
Recent Initiatives: Fictional Company: Recent strategic initiatives include expanding its product portfolio and forming partnerships with distribution companies.
Summary
TNF Pharmaceuticals, Inc. is a growing pharmaceutical company focused on specialty generics and drug delivery technologies. Its strengths lie in its R&D capabilities and niche market focus, but it faces challenges from larger competitors. Recent acquisitions and strategic initiatives are aimed at driving future growth. The company needs to focus on sustainable revenue and market share growth to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional data generated for this exercise.
Disclaimers:
The information provided is based on a fictional company and is for illustrative purposes only. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TNF Pharmaceuticals, Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-01-23 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://tnfpharma.com |
Full time employees 2 | Website https://tnfpharma.com | ||
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.